Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.35 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515045 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL20544101 | 0.74 | NFE2L2 (0.39) | MAOBNFE2L2SOS1HSPB1MAOA | |
| SCHEMBL24209436 | 0.72 | NFE2L2 (0.48) | MAOBNFE2L2LOXL2SOS1HSPB1 | |
| SCHEMBL3272026 | 0.71 | — | — | |
| SCHEMBL18873301 | 0.71 | — | — | |
| SCHEMBL15956243 | 0.70 | ACHE (0.68) | NFE2L2CA1CA2CA9ACHE | |
| SCHEMBL6289867 | 0.69 | SOS1 (0.58) | NFE2L2SOS1HSPB1GAA | |
| SCHEMBL351854 | 0.69 | SOS1 (0.58) | NFE2L2SOS1HSPB1GAA | |
| SCHEMBL6290683 | 0.69 | SOS1 (0.58) | NFE2L2SOS1HSPB1GAA | |
| SCHEMBL6552309 | 0.69 | MAOB (0.39) | MAOBNFE2L2AOC2DAOMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023331-B2 | Methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165111-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240059687-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2024-02-22 | — | — | US | disclosed |
| US-11844757-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3897643-B1 | A PYRIDOPYRROLOQUINOXALINE COMPOUND AND ITS MEDICAL USE | INTRA CELLULAR THERAPIES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3838274-B1 | PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALINE DERIVATIVE FOR USE IN THE TREATMENT OF CNS DISORDERS | INTRA CELLULAR THERAPIES INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11773095-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023178113-A2 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230181576-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023069880-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3658145-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019183341-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190175590-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245260-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2019023063-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019023062-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-3407888-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20170319580-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017132408-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319580-A1 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | MAOB 65/4885NFE2L2 1013/4885LOXL2 1888/4885 |
| US-12023331-B2 | Methods | OPRL1, OPRM1, HTR2A | MAOB 504/4885NFE2L2 1111/4885LOXL2 1360/4885 |
| US-10245260-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | MAOB 65/4885NFE2L2 1013/4885LOXL2 1888/4885 |
| US-11773095-B2 | Organic compounds | OPRD1, OPRM1, OPRK1 | MAOB 75/4885NFE2L2 1255/4885LOXL2 2171/4885 |
| US-20240059687-A1 | ORGANIC COMPOUNDS | OPRD1, OPRM1, OPRK1 | MAOB 75/4885NFE2L2 1255/4885LOXL2 2171/4885 |
| US-20240165111-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR3A | MAOB 77/4885NFE2L2 1428/4885LOXL2 1763/4885 |
| US-20230181576-A9 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | MAOB 65/4885NFE2L2 1013/4885LOXL2 1888/4885 |
| US-20190175590-A1 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | MAOB 65/4885NFE2L2 1013/4885LOXL2 1888/4885 |
| US-11844757-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | MAOB 65/4885NFE2L2 1013/4885LOXL2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.